New HOPE-3 Data: Deramiocel Significantly Improves Duchenne Muscular Dystrophy Patient Function
summarizeSummary
Capricor Therapeutics announced compelling new late-breaking Phase 3 HOPE-3 data for Deramiocel in Duchenne Muscular Dystrophy (DMD) at the MDA Conference. The data demonstrated significant functional benefits, including a statistically significant reduction in myocardial fibrosis, improved left ventricular ejection fraction (LVEF) in patients with cardiomyopathy, and an 83% slowing of disease progression in daily activities like eating. This robust clinical evidence, presented just two days after the FDA lifted the Complete Response Letter for Deramiocel, substantially strengthens the drug's profile. With the Biologics License Application (BLA) currently under FDA review and an August 22, 2026 PDUFA target action date, these positive results significantly de-risk the approval process and highlight Deramiocel's potential as a transformative therapy for this severe, rare disease. Investors will now closely monitor the FDA's review process leading up to the PDUFA date.
At the time of this announcement, CAPR was trading at $34.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $4.30 to $40.37. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.